IPNews® – The Federal Circuit ruled in favor of pharmaceutical giant Allergan, saying that two generic-drug manufacturers would infringe its patent if they attempted to make a generic form of Lumigan, a patented drug for glaucoma patients.

Barr Laboratories, Inc. and Sandoz, Inc. were found by the lower court to not have sufficiently proven their…